

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on June 30, 2009.

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

STATEMENT OF SUBSTANCE OF INTERVIEW
Examining Group 1633
Patent Application
Docket No. ARS.126
Serial No. 10/573,369

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Maria B. Marvich, Ph.D.
Art Unit : 1633
Applicants : Philippe Dupraz, Michel Kobr
Serial No. : 10/573,369
Filed : December 26, 2006
Confirm. No. : 2134
For : Leader Sequences for Use in Production of Proteins

MS ISSUE FEE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW UNDER 37 C.F.R. §1.133

The applicants wish to thank Examiner Marvich for the courtesy of the telephonic examiner interview conducted on June 11, 2009 with the undersigned. The remarks set forth in the Interview Summary Form are consistent with the substance of that interview and are believed to address the outstanding issues as discussed during the interview. The interview clarified that Group IV of the restriction requirement should encompass claims 37-40 in part, drawn to a method of producing a polypeptide of interest using a vector comprising a sequence encoding tPA.

Respectfully submitted,

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
P.O. Box 142950
Gainesville, FL 32614-2950

FCE/jb